Loading clinical trials...
Loading clinical trials...
Title: A Single-arm, Open-label, Prospective, Multicenter Safety Study to Evaluate the Occurrence of Essential Fatty Acid Deficiency (EFAD) in Pediatric Patients With Parenteral Nutrition-associated Cholestasis (PNAC) Who Require More Than Eight Weeks of Omegaven Treatment
Conditions
Interventions
Omegaven® (fish oil triglycerides) Injectable Emulsion
Locations
10
United States
Memorial Health Service
Fountain Valley, California, United States
University of California Los Angeles
Los Angeles, California, United States
The University of Chicago
Chicago, Illinois, United States
Children's Hospital Corporation d/b/a Boston Children's Hospital
Boston, Massachusetts, United States
Children's Hospital Medical Center
Cincinnati, Ohio, United States
Board of Regents of the University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Start Date
December 15, 2024
Primary Completion Date
March 1, 2026
Completion Date
March 1, 2027
Last Updated
September 5, 2025
NCT06154174
NCT06115148
NCT03529019
NCT06869850
NCT06706661
NCT06049680
Lead Sponsor
Fresenius Kabi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions